Update to an open-label clinical trial of vismodegib as neoadjuvant before surgery for high-risk basal cell carcinoma (BCC).

Abstract

22 weeks), whereas in 1 histologically tumor-free patient tumor recurrence was evident within an 18month follow-up period. Figs 1 and 2 show clinical improvement and histologic changes in a nodular BCC treated with ascorbic acid solution. Although antitumor efficacy of vitamin C has been disputed, results of recent studies suggest reconsideration of its… (More)
DOI: 10.1016/j.jaad.2016.02.1235

Cite this paper

@article{Kwon2016UpdateTA, title={Update to an open-label clinical trial of vismodegib as neoadjuvant before surgery for high-risk basal cell carcinoma (BCC).}, author={Gina Kwon and Mina Sarah Ally and Irene Bailey-Healy and Anthony E. Oro and Jinah Kim and Anne Lynn S. Chang and Sumaira Zareen Aasi and J. H. Tang}, journal={Journal of the American Academy of Dermatology}, year={2016}, volume={75 1}, pages={213-5} }